Traders Buy High Volume of SELLAS Life Sciences Group Call Options (NASDAQ:SLS)

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) was the target of unusually large options trading activity on Tuesday. Investors bought 75,479 call options on the company. This is an increase of approximately 114% compared to the typical daily volume of 35,245 call options.

Institutional Investors Weigh In On SELLAS Life Sciences Group

A number of large investors have recently added to or reduced their stakes in the business. Larson Financial Group LLC bought a new position in SELLAS Life Sciences Group during the fourth quarter worth $26,000. BNP Paribas Financial Markets increased its holdings in shares of SELLAS Life Sciences Group by 89.2% in the third quarter. BNP Paribas Financial Markets now owns 19,724 shares of the company’s stock valued at $32,000 after purchasing an additional 9,299 shares during the last quarter. Concurrent Investment Advisors LLC bought a new position in shares of SELLAS Life Sciences Group in the fourth quarter valued at about $38,000. Beacon Pointe Advisors LLC bought a new position in shares of SELLAS Life Sciences Group in the fourth quarter valued at about $38,000. Finally, California State Teachers Retirement System lifted its stake in shares of SELLAS Life Sciences Group by 22.4% during the 1st quarter. California State Teachers Retirement System now owns 9,337 shares of the company’s stock worth $39,000 after buying an additional 1,709 shares during the last quarter. Institutional investors own 17.38% of the company’s stock.

SELLAS Life Sciences Group Stock Performance

Shares of NASDAQ:SLS opened at $10.09 on Wednesday. SELLAS Life Sciences Group has a 52-week low of $1.39 and a 52-week high of $15.88. The company has a market capitalization of $1.98 billion, a P/E ratio of -43.87 and a beta of 2.42. The company has a 50-day simple moving average of $10.48 and a 200 day simple moving average of $6.74.

SELLAS Life Sciences Group (NASDAQ:SLS) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.01.

Analysts Set New Price Targets

A number of research firms recently weighed in on SLS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research report on Friday, July 17th. Alliance Global Partners reissued a “buy” rating on shares of SELLAS Life Sciences Group in a research report on Monday, July 6th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, SELLAS Life Sciences Group currently has a consensus rating of “Hold” and a consensus target price of $10.00.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.